SCHEMBL5650652

SCHEMBL5650652

O=C(O)Nc1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.38
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 4/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 1/20 0.37
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
RECQL P46063 2/20 0.34
KDM4E B2RXH2 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
MEN1 O00255 1/20 0.34
CYP2C9 P11712 1/20 0.34
HTT P42858 1/20 0.34
TGM2 P21980 2/20 0.34
JUN P05412 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ADORA1 P30542 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652117 0.90 CYP1A2 (0.41) ADORA3KMT2AALDH1A1MAPTLMNA
SCHEMBL5648743 0.90 IKBKB (0.40) ADORA3KMT2AALDH1A1MAPTLMNA
SCHEMBL5653932 0.85 ABL1 (0.38) ALDH1A1MAPTLMNARECQLKDM4E
SCHEMBL5653218 0.84 CHEK1 (0.36) ADORA3KMT2AALDH1A1MAPTLMNA
SCHEMBL5650705 0.80 KMT2A (0.43) KMT2AALDH1A1MAPTLMNARECQL
SCHEMBL5648185 0.80 MAT2A (0.38) KMT2AALDH1A1MAPTLMNAKDM4E
SCHEMBL5649654 0.78 ALDH1A1 (0.44) KMT2AALDH1A1MAPTRECQLKDM4E
SCHEMBL5652629 0.78 PLK1 (0.41) ADORA3KMT2AALDH1A1MAPTLMNA
SCHEMBL5654089 0.77 KMT2A (0.38) KMT2AALDH1A1MAPTLMNAKDM4E
SCHEMBL5649021 0.76 KMT2A (0.39) KMT2AALDH1A1MAPTLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ADORA3 1612/4885KMT2A 1815/4885ALDH1A1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.